759 reports of this reaction
1.4% of all DESVENLAFAXINE SUCCINATE reports
#19 most reported adverse reaction
HYPERHIDROSIS is the #19 most commonly reported adverse reaction for DESVENLAFAXINE SUCCINATE, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. There are 759 FDA adverse event reports linking DESVENLAFAXINE SUCCINATE to HYPERHIDROSIS. This represents approximately 1.4% of all 53,036 adverse event reports for this drug.
Patients taking DESVENLAFAXINE SUCCINATE who experience hyperhidrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERHIDROSIS is a less commonly reported adverse event for DESVENLAFAXINE SUCCINATE, but still significant enough to appear in the safety profile.
In addition to hyperhidrosis, the following adverse reactions have been reported for DESVENLAFAXINE SUCCINATE:
The following drugs have also been linked to hyperhidrosis in FDA adverse event reports:
HYPERHIDROSIS has been reported as an adverse event in 759 FDA reports for DESVENLAFAXINE SUCCINATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERHIDROSIS accounts for approximately 1.4% of all adverse event reports for DESVENLAFAXINE SUCCINATE, making it a notable side effect.
If you experience hyperhidrosis while taking DESVENLAFAXINE SUCCINATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.